Insulin Pumps, Including Sensor-Augmented, Enter Competitive Bidding

Now that insulin pumps are part of CMS’ competitive bidding program, there is a possibility of reimbursement reductions down the road. And in a separate process, CMS denied Medtronic’s request to establish a new HCPCS code for sensor-augmented insulin pumps.

The start of 2014 is also the beginning of CMS’ implementation of contracts and prices for the round-one recompete of Medicare’s durable medical equipment, prosthetics, orthotics and supplies competitive bidding program, which includes insulin infusion pumps among its six product categories.

In a separate process, CMS denied Medtronic PLC’s request to establish a new Healthcare Common Procedure Coding System code for sensor-augmented insulin pumps in December 2013.

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.